Replies to post #17313 on BioCurex, Inc.(fka BOCX)

[Kag]

Odd Kelly,
There appears to be more here than Dr. Friedlander not finding anything on the Abbott deal. Dr. Friedlander's comments actually were focused on the claims made on BioCurex's Histo-RECAF (TM)test.

The following is found in the November 14, 2008 SEC 10-Q filing:

“Biocurex is involved in developing cancer detection technology and:
Has developed a cancer detection kit which stains cancer cells, thereby allowing a pathologist to easily view the cancer cells with the use of a microscope,”

In the next paragraph of the same SEC filing the following is also stated:
“Due to the costs involved in manufacturing and marketing, Biocurex plans to license its Histo-RECAF(TM) and Cryo-RECAF(TM) technology to third parties. As of September 30, 2008, Biocurex had not sold any Histo-RECAF(TM) or Cryo-RECAF(TM) test kits and had not licensed the technology pertaining to these kits to any third parties.”

BioCurex’s current website does make the following claim: "Results have consistently proven that BioCurex successfully detects over 90% of all cancers in blood or tissue samples - levels significantly above any present method." Notice that the previous sentence includes “tissue samples”.

Medical Pathologist, Dr. Ed Freidlander. Has written the following during 2008:
“In the meantime, I have contacted the company and expressed an interest in working with them to see whether their claims can withstand scrutiny by the usual methods of science. As a pathologist, it would be a simple matter to confirm or refute the claim, made in the review, that cancers stain and non-cancerous tissue does not stain.”
“Follow-up (August 31, 2008): Despite their expressed eagerness to have independent review, the promoters have not responded to my e-mails.”

My comment: Investors should be curious as to why there was no response to Dr. Freidlander’s emails by BioCurex management. kag

[Gold Seeker]

Odd Kelly, I am not saying the tech is bad. I do think it works but my only question is the extent of the market RECAF can develop.

You ask why Inverness would pay a million dollars? Well, I personally think they planned on using Abbott as the market leader for the test. I thought that after Abbott presented the information at the 2007 ISOBM that Abbott would indeed take RECAF to market and Inverness probably thought likewise. Remember, Inverness signed three months AFTER that ISOBM presentation. Would they have paid that million if they had known Abbott was not going to proceed? I personally doubt if they would have signed at all but that's just my opinion.

As for the information on Abbott that the "path guy" could not find, the press release is old and has fallen off the list for Abbott. It has been gone for quite a while but no one has ever commented on it. That frustrating redirector on the Biocurex website sends you NOWHERE.

The Path guy has some positive things to say about the test. My only question is why Dr. Moro did not respond.